Related Experiment Video
Updated: Aug 6, 2026

09:36
Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022
Digestive enzyme replacement in very preterm infants: a prospective observational study
Sina Keidel1, Sven Wellmann2, Holger Michel2
1Department of Neonatology, Charité Universitätsmedizin Berlin, Berlin, Germany. sina.keidel@charite.de.
European Journal of Clinical Nutrition
|August 5, 2026
Summary
Exogenous digestive enzyme replacement significantly improved weight gain in very preterm infants suffering from temporary exocrine pancreatic insufficiency. This intervention offers a promising approach to enhance growth in vulnerable neonates.
Area of Science:
- Neonatalogy
- Pediatric Gastroenterology
- Nutritional Science
Background:
- Very preterm infants often exhibit poor postnatal growth despite adequate enteral nutrition.
- This growth deficit is frequently associated with transient exocrine pancreatic insufficiency, evidenced by low fecal pancreatic elastase-1 (FPE-1) concentrations.
- Exogenous digestive enzyme supplementation is being explored as a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy of exogenous digestive enzyme replacement in improving growth velocity in very preterm infants with low FPE-1 concentrations.
- To assess the impact of enzyme therapy on daily weight gain, and weight gain relative to protein and caloric intake.
Main Methods:
- A bicentric prospective observational study was conducted on very preterm infants (<32 weeks gestational age, <1500g birth weight) with low FPE-1 (<200 µg/g).
- Infants received a specific dosage of lipase and protease enzymes with each feeding, with dosage adjustments based on body weight.
- Growth velocity was compared during the 14 days before and the 14 days after enzyme initiation.
Main Results:
- Seventy-one infants were included, with a median birth weight of 700g and gestational age of 25.4 weeks.
- Daily weight gain significantly increased from 14.7 to 19.5 g/kg/d post-intervention (p < 0.001).
- Relative weight gain per kg protein and per kcal fed also showed significant improvements (p < 0.001). Enzyme efficacy was more pronounced with pasteurized milk compared to raw milk.
Conclusions:
- Exogenous digestive enzyme administration is associated with enhanced weight gain in very preterm infants experiencing transient exocrine pancreatic insufficiency.
- This therapeutic approach demonstrates potential for optimizing growth outcomes in this vulnerable population.
- The type of milk feeding (pasteurized vs. raw) may influence the effectiveness of enzyme replacement therapy.
Related Concept Videos
What is Monogastric Digestion?
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
Protein Digestion
Protein digestion begins in the stomach, where the highly acidic environment can easily disrupt protein structure by exposing the peptide bonds of polypeptide chains. After polypeptide chains are broken into individual amino acids by a series of digestive enzymes, the amino acids are transported to the liver via the bloodstream to produce energy.
Enzyme-linked Receptors
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

